We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

The Native Antigen Company Introduces Novel Coronavirus Antigens


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "The Native Antigen Company Introduces Novel Coronavirus Antigens"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Native Antigen Company has announced the commercial introduction of its Novel Coronavirus antigens, derived from the emerging Wuhan strain. These recombinant proteins are designed to offer scientists high-quality reagents to support ongoing infectious disease research, and the development of diagnostics and vaccines.

The Native Antigen Company has developed rapid response manufacturing capabilities to produce reagents for emerging epidemic diseases according to the World Health Organisation's R&D Blueprint, which urges the accelerated development of vaccines and the increased availability of accurate and reliable diagnostics for priority emerging infectious diseases. These antigens have been derived specifically from the newly identified Novel Coronavirus (2019-nCoV) using The Native Antigen Company’s proprietary mammalian, VirtuE expression system. This system is able to introduce proper protein folding and post-translational modifications to recombinant proteins, which are essential for full biological and antigenic activity.

Advertisement